Capricor Therapeutics (CAPR) Net Cash Flow (2010 - 2026)
Capricor Therapeutics (CAPR) posted quarterly Net Cash Flow of -$182.4 million for Q1 2026, down 1141.99% year-over-year from $17.5 million in Q1 2025, and down 167.98% quarter-over-quarter from $268.3 million in Q4 2025.
Capricor Therapeutics (CAPR) Net Cash Flow (2010 - 2026) Analysis & Trends
Capricor Therapeutics' Net Cash Flow history runs 17 years deep, the most recent figure standing at -$182.4 million for Q1 2026.
- In Q1 2026, Net Cash Flow fell 1141.99% year-over-year to -$182.4 million; the TTM figure through Mar 2026 stood at $76.6 million (up 239.36% YoY), while the FY2025 annual figure was $276.6 million, up 8215.36% from the prior year.
- Net Cash Flow for Q1 2026 stood at -$182.4 million, down from $268.3 million in the prior quarter.
- The five-year high for Net Cash Flow was $268.3 million in Q4 2025, with the low at -$182.4 million in Q1 2026.
- The 5-year median for Net Cash Flow is -$768395.0 (2023), against an average of $4.1 million.
- The sharpest annual moves came in 2024 and 2026: Net Cash Flow surged 6867.31% in 2024, then slumped 1141.99% in 2026.
- Capricor Therapeutics' Net Cash Flow stood at $1.2 million in 2022, then soared by 380.01% to $5.7 million in 2023, then plunged by 1099.8% to -$57.1 million in 2024, then jumped by 570.02% to $268.3 million in 2025, then sank by 167.98% to -$182.4 million in 2026.
- Business Quant data shows CAPR's Net Cash Flow at -$182.4 million in Q1 2026, $268.3 million in Q4 2025, and -$3.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Capricor Therapeutics | 383.47 Mn | 383.47 Mn | - | -182.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -182.43 Mn |
| Mar 31, 2026 | -182.43 Mn |
| Dec 31, 2025 | 268.34 Mn |
| Dec 31, 2025 | 268.34 Mn |
| Sep 30, 2025 | -3.73 Mn |
| Sep 30, 2025 | -3.73 Mn |
| Jun 30, 2025 | -5.55 Mn |
| Jun 30, 2025 | -5.55 Mn |
| Mar 31, 2025 | 17.51 Mn |
| Mar 31, 2025 | 17.51 Mn |
| Dec 31, 2024 | -57.09 Mn |
| Dec 31, 2024 | -57.09 Mn |
| Sep 30, 2024 | 57.69 Mn |
| Sep 30, 2024 | 57.69 Mn |
| Jun 30, 2024 | 4.47 Mn |
| Jun 30, 2024 | 4.47 Mn |
| Mar 31, 2024 | -8.48 Mn |
| Mar 31, 2024 | -8.48 Mn |
| Dec 31, 2023 | 5.71 Mn |
| Dec 31, 2023 | 5.71 Mn |